Fatty Acid Biosynthesis Inhibitors─Fabimycin and Triclosan─Trigger Distinct Resistance Mutations in FabI and Potently Kill Gram-Negative Pathogens.

Abstract excerpt

In an effort to develop efficacious antibacterials that engage targets for which there is no preexisting resistance, inhibition of the enoyl-acyl carrier protein reductase FabI has shown promise, with triclosan and fabimycin as representative members of the two major drug classes that show activity against important bacterial pathogens. Here, we use a morbidostat and whole-genome sequencing approach to...

Topics

• Triclosan
• Anti-Bacterial Agents
• Enoyl-(Acyl-Carrier-Protein) Reductase (NADH)
• Mutation
• Microbial Sensitivity Tests